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Abstract
Peroxisome proliferator activated receptors (PPARs d, a and c) are closely related transcription factors that exert distinct
effects on fatty acid and glucose metabolism, cardiac disease, inflammatory response and other processes. Several groups
developed PPAR subtype specific modulators to trigger desirable effects of particular PPARs without harmful side effects
associated with activation of other subtypes. Presently, however, many compounds that bind to one of the PPARs cross-
react with others and rational strategies to obtain highly selective PPAR modulators are far from clear. GW0742 is a synthetic
ligand that binds PPARd more than 300-fold more tightly than PPARa or PPARc but the structural basis of PPARd:GW0742
interactions and reasons for strong selectivity are not clear. Here we report the crystal structure of the PPARd:GW0742
complex. Comparisons of the PPARd:GW0742 complex with published structures of PPARs in complex with a and c selective
agonists and pan agonists suggests that two residues (Val312 and Ile328) in the buried hormone binding pocket play
special roles in PPARd selective binding and experimental and computational analysis of effects of mutations in these
residues confirms this and suggests that bulky substituents that line the PPARa and c ligand binding pockets as structural
barriers for GW0742 binding. This analysis suggests general strategies for selective PPARd ligand design.
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Introduction
It is important to develop rational strategies for development of
highly selective nuclear hormone receptor (NR) ligands; homology
between closely related family members means that drugs which
activate particular NRs can cross-react with others, often
triggering undesirable side effects. There are three peroxisome
proliferator activated receptor (PPAR) subtypes termed PPARb/d
(hereafter d), PPARa and PPARc with different expression profiles
and actions [1]. PPARd activation improves overall metabolic
profile. While no PPARd agonists are yet approved for human use,
they have been shown to enhance fatty acid oxidation in skeletal
muscle, reduce serum triglycerides, increase serum high density
lipoprotein (HDL) cholesterol and stimulate aspects of reverse
cholesterol transport, improve glucose homeostasis, and trigger
thermogenesis and weight loss [2,3,4]. Additionally, PPARd
ligands even enhance metabolic benefits of exercise training and
can act as an exercise mimetics in their own right. Whereas
agonists that activate other PPARs exert beneficial effects, these
actions are tempered by deleterious side effects. PPARc agonists
(thiazolidinediones, TZDs) are potent insulin sensitizers [5,6] but
cause edema, gain in fat mass, increased bone fractures and
elevated risk of heart attack which have led to restrictions in their
use. Fibrates that activate PPARa [6] reduce serum triglycerides
and increase HDL but PPARa agonists are carcinogenic in
rodents. Dual specificity ligands (glitazars) that simultaneously
activate PPARa and PPARc elicit significant improvements in
insulin sensitivity and atherogenic serum lipid profiles in humans,
but were discontinued because of cardiovascular events and
increased death rate, carcinogenicity in rodents, liver toxicity and
kidney damage. Current indications suggest that desirable PPARd
agonists should not cross-react with other PPARs.
PPARs exhibit complex ligand binding modes. PPAR C-
terminal ligand binding domains (LBDs) are 60–70% homolo-
gous [7] with large (<1300A ˚ 3) Y-shaped ligand binding pockets
(LBPs) composed of three sub-arms (Arms I, II and III) that
display significant homology between the subtypes. Arm I is
predominantly polar, well conserved and includes residues that
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and Arm III are predominantly hydrophobic and less well
conserved among PPARs [9,11]. All three PPARs bind a variety
of natural and synthetic ligands, none of which completely fills
the LBP and PPAR ligands can adopt different binding modes
[9]. Many agonists, however, conform to a standard pharma-
cophoric model [12] in which ligands comprise a hydrophilic
head group that binds Arm I and a hydrophobic tail that binds
Arm II and/or Arm III.
GW0742 (Fig. 1) was developed using standard medicinal
chemistry and conforms to the pharmacophoric model of PPAR
ligands, yet displays 300–1,000 fold selectivity for PPARd versus
other PPARs [13] and full PPARd agonist actions in cell culture
and animal models [14,15,16,17]. Presently, however, the
structural basis for this high selectivity is not obvious. Whereas
X-ray structures of PPARd in complex with PPARd-specific
partial agonists are reported and reveal ligand binding within parts
of Arms II and III far from H12, X-ray structures of PPARd in
complex with GW0742 or other PPARd selective agonists are not
publicly reported.
Here, we report the resolution of the structure of the PPARd
LBD in complex with GW0742 to gain insights into selective
binding of this ligand and methods to improve PPARd-selective
binding of agonists that conform to the standard pharmacophoric
model. Comparisons of the docking mode of this GW0742 with
those of highly hPPARa and hPPARc selective agonists with their
respective receptors and a pan agonist with all three PPARs
coupled to mutational and computational analysis of effects of
PPARd mutants identifies two LBP residues (Val312 and Ile328)
that are crucial for specificity, pinpointing regions of the LBP that
could be explored in new ligand development.
Results and Discussion
hPPARd-LBD:GW0742 Complex Structure
The crystal structure of hPPARd-LBD with GW0742 was
determined in the P212121 space group, at 1.95 A ˚ resolution
(Fig. 2A). The final model consists of a monomer in the
asymmetric unit, composed of residues Gln171 to Tyr441
(hPPARd numbering). One molecule of GW0742, 185 water
molecules and one glycerol molecule were also resolved in the
structure. All protein residues occupy favorable regions of the
Ramachandran plot; data collection statistics are given in Table 1.
Overall folding resembles previous PPARd LBD structures and is
not further described.
GW0742 occupied the Y-shaped LBP and adopted a position
predicted by the pharmacophoric model of PPAR ligands
[8,9,10,18] (Fig. 2B). The hydrophilic head group interacts with
arm I and the hydrophobic tail, comprising the thiazole and the
fluorine substituted phenyl ring, is positioned mostly in arm II.
The linker connecting the head and tail groups lies close to H3
(Fig. 2B). In total, GW0742 made 29 ligand interactions with
PPARd pocket, including three polar interactions and 26 apolar
interactions (Table S1).
Polar interactions mostly involve the ligand hydrophilic head
group and residues in Arm I and appear similar to other PPAR
agonists with their respective PPARs [9]. By analogy, these
interactions are probably responsible for maintaining the locked
agonist conformation of activation helix 12. One ligand carbox-
ylate oxygen engages in hydrogen bonds with the side chains of
residues His413 (helix 10/11) and Tyr437 (helix 12) - Figure 2B.
The other carboxylate oxygen contacts the His287 side chain from
PPARd helix 7.
Apolar interactions involved residues in all three Arms. In Arm
I Phe246, Phe291, His413, Ile327, Leu433 and Cys249 side chains
contact ligand. In arm II, Val245, Val305, Val312, Leu317 and
Ile328 side chains bind ligand and two residues that lie within Arm
III, Thr252 and Leu294, are also engaged in ligand contact.
We were not able to discern any GW0742 contacts with amino
acids that were completely unique to PPARd and could account
for selective ligand binding (Fig. 3) [18]. Of 12 Arm I amino acids
(Fig. 3A); eight (Phe246, Cys249, His287, Phe291, Ile327, His413,
Leu433 and Tyr437) contact GW0742. Of these, His287, Phe291
and Ile327 vary between PPARs and none are exclusive to
PPARd; Phe291 and Ile327 are conserved in PPARa and His287
is conserved in PPARc. Of 12 Arm II residues (Fig. 3B), five
(Val245, Val305, Val312, Leu317 and Ile328) are involved in
ligand contact. Of these; Leu317 is identical in all subtypes and
there are conserved substitutions at the other four positions. Of
nine Arm III residues (Fig. 3C), only two contact ligand; Leu294 is
conserved in the three PPAR subtypes and Thr252 is conserved in
PPARa with a non-conserved substitution in PPARc.
Potential Steric Hindrance to GW0742 Binding in PPARa
and c
We next compared the PPARd:GW0742 structure with
analogous structures of PPARa and c LBDs in complex with
representative selective agonists (GW735 and Rosiglitazone) and
the three PPARs with a pan agonist, indeglitazar (PDB ids: 2P54
[19], 2PRG [20] and 3ET2, 3ET3 and 3ET1, respectively [21].
All four ligands conform to the standard PPAR ligand pharma-
cophoric model [22] and adopt a similar position in the pocket
(Fig. 4). However, GW0742 binding exhibited two features that
were unique. First, the linker group is displaced from H3 relative
to other PPAR subtype selective ligands (Fig. 4A). This shift was
also seen in the PPARd structure with the non-selective agonist
indeglitazar (not shown), suggesting that it does not account for
selectivity. More interestingly, the GW0742 hydrophobic tail
occupies the entrance to Arm II, unlike GW735 and Rosiglitazone
tails which are directed towards Arm III between the helices 3 and
2 ` (Fig. 4A and B).
Comparison of amino acids that form the PPARd Arm II
entrance with equivalent regions of PPARa and PPARc revealed
two substitutions which could potentially form barriers to
GW0742 binding and could block access to PPARc and PPARa
Arm II; dVal312 is replaced by bulkier side chains aIle339 and
cMet376 and dIle328 is substituted by the bulkier methionine in
both PPARs (aMet355 and cMet392) (Fig. 4B). Other nearby
substitutions do not exhibit similar potential to block GW0742
binding. Some introduce similarly sized amino acids (dHis287/
aTyr314/cHis351; dPhe291/aPhe318/cTyr355; dVal245/
Figure 1. Three-dimensional structure of PPARd-selective
agonist GW0742, as found in our hPPARd:GW0742 crystal
structure (PDB id 3TKM). Typical structural features of PPAR agonists
are displayed. Carbon, fluoride, sulfur, oxygen and nitrogen atoms are
colored white, light grey, grey, dark grey and black, respectively.
doi:10.1371/journal.pone.0033643.g001
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PPARc-specific substitutions (dIle327/aIle354/cPhe391 and
dThr252/aThr279/cArg316) introduce residues with flexible side
chains that are not likely to block GW0742 binding; cPhe391
contacts Rosiglitazone (PDB id 2PRG), but faces away from ligand
in the PPARc:Indeglitazar structure (PDB id 3ET3) (Figure S1)
and cArg316 faces away from both ligands.
Site Directed Mutagenesis Confirms Key Roles for
dVal312 and dIle328 in GW0742 Binding
To determine whether dVal312 and dIle328 are important for
PPARd selective activation by GW0742, we introduced Met
substitutions at both positions: PPARd-LBD/Val312Met and
PPARd-LBD/Ile328Met and determined effects of mutations on
responses to different ligands. As expected [13], GW0742 was a
potent activator of PPARd (EC50=3.25 nM) relative to PPARa or
PPARc; it was not possible to derive accurate EC50 values for the
latter curves. Both PPARd mutants displayed similar levels of
activation at very high GW0742 concentrations, but EC50 values
were greatly increased relative to wild type receptor, indicative of
reduced potency (Fig. 5A). Half-maximal responses were one order
of magnitude higher (66.0 nM) for PPARdIle328Met relative to
wild type receptor and EC50 values for PPARdVal312Met mutant
were even higher, it was not possible to achieve an adequate
estimate of EC50 values similar to wild type PPARa and PPARd.
The met substituents did not completely change overall PPARd
ligand binding profile. The pan-PPAR agonist benzafibrate [23];
activated PPARa, PPARd and PPARc with descending efficacy
(Fig. 5B) and PPARd Val312Met activation was about 2.5 fold,
similar to wild type PPARd and PPARdIle328Met was similar to
that of PPARc (1.5 times of activation). Neither met substituent
enhanced activation by the PPARa selective agonist GW7647
(Fig. 5C) or the PPARc selective agonist rosiglitazone (Fig. 5D).
Thus, the presence of bulky residues at positions 312 and 328
reduces PPARd activation by GW0742 but does not permit
PPARd activation by ligands that bind other subtypes.
Figure 2. Crystallographic structure of the complex hPPARd-LBD:GW0742. (A) The ligand (magenta sticks) occupies the PPARd-LBD (grey
cartoon) and performs interactions with residues belonging to the arm I (yellow), arm II (green) and arm III (orange). (B) Stereo view of the binding
site, showing the electron density calculated for the ligand (omit map, contoured at s=1.0) and the PPARd residues that stabilize the ligand. Polar
interactions between hPPARd-LBD and the GW0742 ligand are shown as dashed lines. Nitrogen, oxygen, sulfur and fluoride atoms are colored blue,
red, yellow and light blue, respectively. The residues from arms I, II and III are colored in yellow, green and orange, respectively. Figures were
generated with the Pymol software (Schro ¨dinger).
doi:10.1371/journal.pone.0033643.g002
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We next modeled PPARd-LBD mutants, docking the ligand
inside the structures. After docking, energy minimization and
molecular dynamics simulation, all the PPARs (a, c, d and the
mutants dVal312M and dIle328M) showed accommodation of
their main chains, with trajectory root mean square deviation
(RMSDs) ranging from 1.3 A ˚ to 1.65 A ˚. Docking analysis revealed
that for all PPARs, GW0742 was able to accommodate itself in the
ligand binding pocket, but considerable conformational changes of
the side chains, which corresponds to the Val312 and Ile328
substitutions, and also in the ligand were observed (data not
shown).
Analysis of RMSDs of Met312 and Ile328, after simulations,
shows that PPARd presents smaller conformational changes in
comparison to the other PPARs (Table 2), clearly revealing
necessity of large side chain adjustments by PPARa, c and the
mutants, in order to accommodate GW0742 ligand.
In summary, we have solved the PPARd-LBD structure in
complex with GW0742, a high potent and selective PPARd
agonist. The ligand follows the binding model predicted to other
PPAR ligands based on the same pharmacoforic groups. The
carboxylate group occupies arm I of the binding pocket while the
hydrophobic tail occupies arm II. Comparison of the structures of
the three PPARs isotypes with agonists allowed us to observe some
subtle differences that could explain the isotype delta ligand
selectivity to GW0742. Specifically, the hydrophobic tail of
GW0742 occupies part of Arm II, unlike equivalent PPARa and
PPARc agonists which dock into Arm III and we propose that the
presence of two residues in PPARd-LBD, Val312 and Ile328, is
intimately related with selectivity. Here, both of these residues are
replaced by amino acids with bulkier side chains in PPARa and
PPARc, and it is likely that these would occlude the entrance to
ArmII in the context of these PPAR subtypes and prevent the
GW0742 hydrophobic tail from docking into its preferred position.
To validate this hypothesis, we performed two single point
mutations, Val312Met and Ile328Met, and conducted cell
activation assays and docking analyses of PPAR isotypes and
mutants using selective ligands for each isotype and confirmed that
Table 1. Crystallographic data collection statistics.
Parameter
Wavelenght (A ˚) 1.46
Space Group P212121
Unit Cell Dimensions (A ˚) 35.466 41.766 96.287
Resolution Range (A ˚) 24.4 (1.95)
Reflections at working set 19134 (2511)
Reflections at test set 978 (135)
Redundancy 5.8 (4.7)
Completeness (%) 99.28 (99.1)
I/d 17.3 (2.6)
Rfree 24.5 (30.2)
Rfactor 19.5 (25.6)
RMSD bond lengths (A ˚) 0.004
RMSD bond angles (degrees.) 1.006
Average B-factor 24.85
Ramachandran outliers 0/303
Values in parentheses indicate the high-resolution shell.
doi:10.1371/journal.pone.0033643.t001
Figure 3. Alignment of amino acid residues forming the
binding site of the different human PPAR isotypes. Residues
placed in arm I (A), arm II (B) and arm III (C) are shown. Residues
involved in the hPPARd-LBD:GW0742 interactions are underscored.
Residues in black, bold and gray represent identical residues, residues
with same chemical character and residues with different chemical
character, respectively.
doi:10.1371/journal.pone.0033643.g003
Figure 4. Crystallographic structure superposition of selective
ligands to each PPAR isotype. Helices from PPAR are shown as
yellow, magenta and green cartoons for PPARa, d and c, respectively.
The a selective ligand, GW735 (PDBid: 2P54), the d selective ligand,
GW0742, and the c selective ligand, rosiglitazone (PDBid: 2PRG), are
shown as yellow, magenta and green sticks, respectively. Oxygen,
nitrogen, sulfur and fluoride atoms are shown in red, blue, yellow and
light blue, respectively. A) Upper vision of the binding site. B)
Stereoscopic view of the PPAR binding sites, highlighting the
importance of Val312 and Ile328 in GW0742 accommodation and
GW735 and rosiglitazone displacement, presumably due to the
presence of bulky substitutions. Ligands GW735, GW0742, rosiglitazone
are painted in yellow, magenta and green, respectively.
doi:10.1371/journal.pone.0033643.g004
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positions reduces activation of PPARd by GW0742 but not other
non-selective PPAR ligands. Our results indicate that ligands
carrying short linkers and large and rigid hydrophobic tails find
difficulties in being accommodated into PPARa and PPARc arm
II, probably as a consequence of the bulky amino acid substitution
found in these isotypes. We propose that this hypothesis brings
some light to the understanding of the molecular basis of PPAR
selective ligands mode of interaction and may be helpful in further
rational design of PPAR selective agonists.
Our results agree with previous studies which link effects of
amino acid substitution in PPARs binding sites upon ligand
binding to the binding site shape, which, in turn, limits ligand
entry and accommodation [8,9,10,18,24]. PPARd presents the
smaller arm I as a consequence of the presence of Met417 in
the place of the Val residue present in PPARa, what explains the
relative low affinity of this isotype for some fibrates and other
Figure 5. PPAR transactivation assays. PPAR activation induced by (A) the d-selective agonist GW0742; (B) the pan-agonist benzafibrate; (C) the
a-selective agonist GW7647 and (D) the c-selective agonist rosiglitazone. All data were normalized by the level of Renilla luciferase activity. &/#
wtPPARd, m/xx PPARdVal312Met,N///PPARdIle328M, /=PPARa and b/ PPARc.
doi:10.1371/journal.pone.0033643.g005
Table 2. RMSD values of the residues dMet312, dIle328 and its corresponding residues from PPAR a, c and mutants after GW0742
docking and molecular dynamic simulations.
model RMSD of dMet312 position(A ˚)R M S D o f dIle328 position (A ˚)
PPARd 0.3 0.6
PPARa 0.6 1.1
PPARc 11 . 8
PPARd V312M 0.9 0.7
PPARd I328M 0.3 0.9
doi:10.1371/journal.pone.0033643.t002
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In the same direction, the presence of Tyr344 in PPARa arm III
reduces the size of the binding site entrance, causing steric
restrictions to ligand entry [8]. Substitutions in arm II were mainly
related to change the accommodation of the main hydrophobic
part of the ligands [8,18]. This mode of selectivity is very different
from that of other NRs, such as thyroid hormone and estrogen
receptors, where selectivity often relates to enhanced contacts
between ligand and specific amino acids within the pocket. It will
be important to understand the rules that link pocket shape to
ligand position in PPARs to better develop new selective ligands.
Methods
Protein Expression and Purification
The human PPARd LBD plasmid (amino acids 171–441) with
cDNA inserted into pET15 vector (Novagen, USA) was trans-
formed in BL21(DE3) Escherichia coli. Protein expression was
performed in LB culture, induced with 1 mM IPTG, at 18uC for
12 h. Cells were harvested and ressuspended in a 20 ml of buffer
A (20 mM Hepes pH 7.5, 300 mM NaCl, 5% glycerol, 10 mM b-
mercaptoethanol, 10 mM PMSF and 250 mg/mL lysozyme) per
liter of culture. The lysate was sonicated, clarified by centrifuga-
tion and loaded onto a Talon Superflow Metal Affinity Resin (BD
Biosciences Clontech, Palo Alto, CA), and eluted with an imidazol
gradient (0–300 mM). The fractions containing the purified
protein were pooled and washed, using centrifugal concentrators
(Amicon, 10 MW cutoff), to remove imidazol. The His-tag was
cleaved with trombin (7 U/mg), at 18uC, overnight. Protein purity
was checked by Coomassie blue-stained SDS-PAGE. Protein
concentrations were determined using the Bradford dye assay (Bio-
Rad, Hercules, CA).
Crystallization
Protein buffer was changed to 20 mM Hepes (pH 7.5), 500 mM
ammonium acetate, 10 mM b- mercaptoethanol, according to [8].
Prior to crystallization, PPARd-LBD (256 mM) was incubated for
4 h with GW0742 (Tocris Bioscience) (1:4 protein:ligand molar
ratio) in DMSO (DMSO final concentration equals to 5%), at
4uC. The sitting-drop vapor diffusion method was used, with drops
containing 2 ml of protein:ligand complex, 0.5 ml of the detergent
n-Octyl-b-D-thioglucoside and 2.5 ml of the reservoir solution
made of 14% (w/v) polyethylene glycol (PEG) 8000, 200 mM
KCl, 40 mM bis-Tris-propane (pH 9.5), 6% propanol, 1 mM
CaCl2. hPPARd-LBD:ligand co-crystals were grown at 18uC and
appeared after 3 days, showing a well-defined geometric form.
Data Collection, Model Refinement and Analysis
Crystals were transferred to a cryo-protecting solution, contain-
ing the well solution plus 10% glycerol, and immediately flash
cooled to 100 K in a nitrogen stream prior to data collection. The
X-ray diffraction data collection was performed at the MX-2
beamline of the Brazilian National Synchrotron Light Laboratory
(LNLS, Campinas, Brazil) [25] using synchrotron radiation of
wavelength 1.459 A ˚ to optimize crystal diffraction efficiency and
the synchrotron-radiation flux of the LNLS storage ring [26]. The
diffraction images were registered on a MAR225 mosaic detector,
with an oscillation of 1u per image. Data reduction was performed
using HKL200/Scalepack package [27].
The X-ray structure of PPARd-LBD (PDB ID: 3ET2) [21] was
used as an initial model for molecular replacement using the
program PHASER [28]. The protein atomic model was improved
through alternated cycles of real space refinement using COOT
[29] and maximum likelihood minimization using PHENIX [30].
Ligand and solvent molecules were included in the last steps of
refinement.
Protein:ligand contacts were analyzed using the Ligplot software
[31], followed by visual inspection using the program COOT [29].
A hydrogen bond distance cutoff of 3.4 A ˚ was applied. Superpo-
sition of different PPAR crystal structures was performed with the
Superpose software [32] and analyzed using the Pymol software
[33].
PDB Accession Code
The atomic coordinates and structure factors of the hPPARd-
LBD:GW0742 crystal complex reported here are deposited in the
Protein Data Bank under code 3TKM.
Site Directed Mutagenesis and Transactivation Assay
Mutations in the hPPARd-LBD were introduced by PCR in an
existing vector PPARdGAL4 [34] with overlapping of mutated
primers and vector using the QuikChange site-directed mutagen-
esis kit (Stratagene). All mutated constructs were verified by
sequencing. The reporter plasmid pGRE-LUC (GAL4 responsive
element, Firefly luciferase reporter vector) and PPARd LBDGal4
inserted in pBIND (Promega). The pRL-TK, that contains Renilla
luciferase, was purchased from Promega (Dual-Luciferase Report
Assay system Promega, Madison, WI).
HepG2 cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DEMEM) supplemented with 10% heat-inactivated fetal
bovine serum, 2 mM glutamin, 50 UI/mL penicillin/streptomy-
cin under 95% air and 5% CO2 at 37uC. For transactivation
assays, the cells were removed by trypsinization and replated in 24
wells plate at density of 1,2610
5 cells/well. Cell transfections were
performed using FuGENE 6 transfection reagent (Roche, Swiss)
with 100 gg of plasmids containing wild-type PPARa,d ou c-LBD
or PPARd-LBD mutants, DBD Gal-4, 50 gg of luciferase reporter
plasmid and 1 ggo fRenilla luciferase plasmid per well. Cells were
treated with different concentrations of agonists of PPARa -
GW7647, PPARd - GW0742 and PPARc - Roziglitazone, in
triplicate 24 h after transfection and incubated for additional 24 h.
Cell lysates were prepared and luciferase assay was performed
using the Dual-Luciferase Report Assay system (Promega, Madison,
WI), following manufacturer instructions. Light emission was
measured by integration over 5 seconds of reaction in a Safire
luminescent counter (Tecan, Tecan US, NC, USA). Firefly
luciferase activity was normalized by the level of Renilla luciferase
activity, as recommended by manufacturers Dual-Luciferase Report
Assay system. Data were fitted using a sigmoidal dose-response
function with corresponding EC50 determination according to
GraphPad Prism software (version 5.0).
Docking and Molecular Dynamics Simulation
The molecular complexes for PPAR a, c, mutants and GW0742
were built using the ligand conformation obtained from crystal-
lographic structure of PPARdLBD:GW0742 complex (PDBid
3TKM). PPAR a and c LBD structures (PDBid 3ET1 and 3ET3
respectively) were superposed to PPARd complex and coordinates
of the ligand were copied to the PPAR a and c structures. Mutant
PPARd-LBD models V312M and I328M were built using the
YASARA software. All structures were submitted to energy
minimization and molecular dynamics simulation using YASARA.
For that, all hydrogen atoms and other missing atoms from the
model were created using force field parameters, obtained from
YAMBER3. A simulation box was defined at 15 A ˚ around all
atoms of each complex. Protonation was performed based on the
pH 7. Cell neutralization was reached filling the box with water
molecules and Na
+/Cl
2 counter ions. A short molecular dynamics
PPAR-Delta Selective Ligand Binding
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water until the density of 0.997 g/ml was reached. A short steepest
descent energy minimization was carried until the maximum atom
speed dropped below 2200 m/s. Then 500 steps of simulated
annealing were performed with a temperature of 0 K. Finally, a
4 ns (nanosecond) simulation at 298 K and a non-bonded cutoff of
7.86 A was performed. A snapshot was saved every 25 ps
(picosecond). Simulation time was adjusted to stabilize the contacts
between protein and ligand.
Supporting Information
Figure S1 Observation of phenylalanine flexibility on PPARc
structures. Superposition of the c-selective ligand rosiglitazone
(green stick), pan-agonist ligand indeglitazar (blue sticks) and the
cPhe391 residue from the respective crystallographic structures for
PDB id 2PRG (green lines) and 3ET3 (green lines). Helix 3 is
shown as a blue and green cartoon. Oxygen, nitrogen, sulfur and
fluoride atoms are shown in red, blue, yellow and light blue,
respectively.
(DOC)
Table S1 Atoms involved in interactions between the GW0742
ligand and hPPARd-LBD, as found in our hPPARd-LBD:
GW0742 crystal structure.
(DOC)
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